Peter Verhamme to Male
This is a "connection" page, showing publications Peter Verhamme has written about Male.
Connection Strength
0.145
-
Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial. EBioMedicine. 2021 Apr; 66:103288.
Score: 0.013
-
Staphylococcus aureus endocarditis: distinct mechanisms of bacterial adhesion to damaged and inflamed heart valves. Eur Heart J. 2019 10 14; 40(39):3248-3259.
Score: 0.011
-
Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation. Eur J Heart Fail. 2019 01; 21(1):129-131.
Score: 0.011
-
Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalization. Semin Thromb Hemost. 2021 Jun; 47(4):362-371.
Score: 0.003
-
Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial. Trials. 2021 Feb 09; 22(1):126.
Score: 0.003
-
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021 03; 192(6):1100-1105.
Score: 0.003
-
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials. 2020 Dec 09; 21(1):1005.
Score: 0.003
-
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials. 2020 Nov 27; 21(1):981.
Score: 0.003
-
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation. 2019 10 29; 140(18):1451-1459.
Score: 0.003
-
Implementing Automated Office Blood Pressure Measurement. Hypertension. 2019 09; 74(3):441-449.
Score: 0.003
-
A comprehensive report of long-term outcomes after catheter-directed thrombolysis for occluded infrainguinal bypass grafts. J Vasc Surg. 2019 10; 70(4):1205-1216.
Score: 0.003
-
Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. Eur Respir J. 2019 02; 53(2).
Score: 0.003
-
Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. Thromb Haemost. 2019 Apr; 119(4):576-585.
Score: 0.003
-
Accuracy of age-adjusted D-dimer to rule out deep vein thrombosis in the elderly. Thromb Res. 2019 02; 174:148-150.
Score: 0.003
-
Diastolic left ventricular function in relation to circulating metabolic biomarkers in a population study. Eur J Prev Cardiol. 2019 01; 26(1):22-32.
Score: 0.003
-
Lemierre Syndrome: Clinical Update and Protocol for a Systematic Review and Individual Patient Data Meta-analysis. Hamostaseologie. 2019 Feb; 39(1):76-86.
Score: 0.003
-
Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018 Aug; 118(8):1439-1449.
Score: 0.003
-
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thromb Res. 2018 08; 168:121-129.
Score: 0.003
-
Desphospho-uncarboxylated matrix Gla protein is a novel circulating biomarker predicting deterioration of renal function in the general population. Nephrol Dial Transplant. 2018 07 01; 33(7):1122-1128.
Score: 0.003
-
Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry. Intern Emerg Med. 2018 Oct; 13(7):1051-1058.
Score: 0.003
-
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018 04 21; 39(16):1330-1393.
Score: 0.003
-
Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv. 2018 04 10; 2(7):788-796.
Score: 0.003
-
Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition. Thromb Haemost. 2018 05; 118(5):818-829.
Score: 0.003
-
Acute non-cirrhotic portal vein thrombosis : review. Acta Gastroenterol Belg. 2018 Apr-Jun; 81(2):318-322.
Score: 0.003
-
Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. PLoS One. 2018; 13(3):e0194673.
Score: 0.003
-
Epidemiological and histological findings implicate matrix Gla protein in diastolic left ventricular dysfunction. PLoS One. 2018; 13(3):e0193967.
Score: 0.003
-
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. J Am Coll Cardiol. 2018 05 22; 71(20):2306-2315.
Score: 0.003
-
Reproducibility of Retinal Microvascular Traits Decoded by the Singapore I Vessel Assessment Software Across the Human Age Range. Am J Hypertens. 2018 03 10; 31(4):438-449.
Score: 0.003
-
The risk of nephrolithiasis is causally related to inactive matrix Gla protein, a marker of vitamin K status: a Mendelian randomization study in a Flemish population. Nephrol Dial Transplant. 2018 03 01; 33(3):514-522.
Score: 0.003
-
Glomerular function in relation to circulating adhesion molecules and inflammation markers in a general population. Nephrol Dial Transplant. 2018 03 01; 33(3):426-435.
Score: 0.003
-
Conventional and Ambulatory Blood Pressure as Predictors of Diastolic Left Ventricular Function in a Flemish Population. J Am Heart Assoc. 2018 02 08; 7(4).
Score: 0.003
-
Association between cognition and the retinal microvasculature in 11-year old children born preterm or at term. Early Hum Dev. 2018 03; 118:1-7.
Score: 0.003
-
ECG Voltage in Relation to Peripheral and Central Ambulatory Blood Pressure. Am J Hypertens. 2018 01 12; 31(2):178-187.
Score: 0.003
-
Impact of Thrombus Sidedness on Presentation and Outcomes of Patients with Proximal Lower Extremity Deep Vein Thrombosis. Semin Thromb Hemost. 2018 Jun; 44(4):341-347.
Score: 0.003
-
Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018 02; 162:7-14.
Score: 0.003
-
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624.
Score: 0.003
-
Age-adjusted D-dimer to rule out deep vein thrombosis: findings from the PALLADIO algorithm. J Thromb Haemost. 2018 02; 16(2):271-278.
Score: 0.003
-
Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414.
Score: 0.003
-
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017 08 03; 377(5):431-441.
Score: 0.002
-
Left ventricular function in relation to chronic residential air pollution in a general population. Eur J Prev Cardiol. 2017 09; 24(13):1416-1428.
Score: 0.002
-
Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Press. 2017 12; 26(6):321-331.
Score: 0.002
-
PEAR1 is not a major susceptibility gene for cardiovascular disease in a Flemish population. BMC Med Genet. 2017 04 27; 18(1):45.
Score: 0.002
-
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 03 30; 376(13):1211-1222.
Score: 0.002
-
Left Ventricular Structure and Function in Relation to Environmental Exposure to Lead and Cadmium. J Am Heart Assoc. 2017 02 01; 6(2).
Score: 0.002
-
Outcome-driven thresholds for ambulatory pulse pressure in 9938 participants recruited from 11 populations. Hypertension. 2014 Feb; 63(2):229-37.
Score: 0.002